 T-DOC ® NXT  Clinical Study  
 
Confidential © 201 8 LABORIE  
 
 
 
 
STUDY NUMBER:  
TDOC -NXT-01 
 
STUDY NAME:  
T-DOC® NXT Clinical Investigation:  
Assessing the Performance, Safety and Usability of our Next Generation T -DOC® 
NXT Catheter for Performing Urodynamic Studies  
 
DOCUMENT : 
CLINICAL STUDY PROTOCOL  
 
NCT NUMBER:  
[STUDY_ID_REMOVED]  
 
DOCUMENT VERSION & DATE:  
Version 1.0  
June 26, 2018  
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 1 of 35 
 
CLINICAL STUDY PROTOCOL  
 
DEVICE:  
T-DOC® NXT Air-Charged Urodynamic Catheters  
 
 
STUDY NUMBER:  
 TDOC -NXT-01 
 
 
STUDY NAME:  
T-DOC® NXT Clinical Investigation:  
Assessing the Performance, Safety and Usability of our Next Generation T-DOC®  NXT Catheter 
for Performing Urodynamic Studies  
 
Version 1.0 
June  26, 2018  
 
  
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 2 of 35 
 
TDOC -NXT-01  
T-DOC® NXT Clinical Investigation:  
Assessing the Performance, Safety and Usability of our Next Generation T-DOC®  NXT Catheter 
for Performing Urodynamic Studies  
 
KEY SPONSOR STUDY TEAM  
Sponsor  
Laborie Medical Technologies Canada ULC  
[ADDRESS_652996]  
Mississauga, Ontario, Canada, L4V1X1  
+[PHONE_10529]  
 
 
   
 
 
 
 
  
  
  

 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 3 of 35 
 
TDOC -NXT-01  
T-DOC® NXT Clinical Investigation:  
Assessing the Performance, Safety and Usability of our Next Generation T-DOC®  NXT Catheter 
for Performing Urodynamic Studies  
CLINICAL STUDY PROTOCOL  
PREPARED BY  [CONTACT_206686]:  
Job function :  
 
 
In signing the box below the approver signifies that they have reviewed the protocol and approve it on the basis that it meets the following 
requirements  
1. The protocol is consistent with the clinical plan  
2. Adequacy of sample size and appropriateness of proposed statistical ana lysis 
3. Accuracy of device description, efficacy and performance characteristics  
4. Biological safety of Investigational and control devices and their appropriateness for human use  
5. Conformance to all applicable regulations  
6. Adequacy in meeting business needs  
CLINICAL STUDY  PROTOCOL  
 
APPROVED BY  [CONTACT_206686] :   
Job function :  
   
 
 
  

 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 4 of 35 
 
TDOC -NXT-01  
T-DOC® NXT Clinical Investigation:  
Assessing the Performance, Safety and Usability of our Next Generation T-DOC®  NXT Catheter 
for Performing Urodynamic Studies  
INVESTIGATOR(S)   
Principal Investigator  
  
 
 
 
 
 
 
 
 
 
[INVESTIGATOR_506205](S)   
 
 
 
 
 
 
 
 
INSTITUTION(S)  
 
 
 
 
 
  
 
 
 
 

 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 5 of 35 
 
TDOC -NXT-01  
T-DOC® NXT Clinical Investigation:  
Assessing the Performance, Safety and Usability of our Next Generation T-DOC®  NXT Catheter 
for Performing Urodynamic Studies  
 
"CONFIDENTIAL INFORMATION"  
Will mean all information provided by [CONTACT_506208] 
"CONFIDENTIA L" by [CONTACT_206689] p arty at the time of disclosure.  If such transmittal 
occurs orally, the transmitting party will promptly reduce such transmittal in writing, mark 
and identify it as confidential, and provide such record to the o ther party.   
Specifical ly excepted fr om this is all information that  
1. was previousl y known by [CONTACT_206690]  
2. is publicly disclosed except by [CONTACT_206691]'s receipt of such informat ion 
3. is rightfully received by [CONTACT_3433] e receiving party without an ex press obligation of confidence  
4. is independently developed by [CONTACT_206693]  
5. is disclosed pursuant to any judicial or government request, requi rement or order, 
provided that the disclosing party takes reasonable steps to provide the other party with 
sufficient prior notice in order to allow the other party to contest such request, 
requirement or order.  
The receiving party will not disclose CONFI DENTIAL INFORMATION without authorization 
from the disclosing party.  This provision shall remain in effect for five (5) years following 
completion of this study.  COMPANY shall be provided with patient information as allowed 
by [CONTACT_506209] c onfidentiality of all such patient information, unless specifically 
required to disclose such information by [CONTACT_2371].  
INVESTIGATOR STATEMENT  
I fully understand the requirements of this study and my role as Investigator. I agree to 
participate and to comply wit h the requirements presented to me by [CONTACT_206707] .  I agree to follow 
the protocol laid out before me and to not deviate from it in any way.  I also agree to document 
all the required information as fully as I can.  
ACCEPTED BY  
[CONTACT_162858]  [INVESTIGATOR_506206]           
 

 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 6 of 35 
 
TDOC -NXT-01  
T-DOC® NXT Clinical Investigation:  
Assessing the Performance, Safety and Usability of our Next Generation T-DOC®  NXT Catheter 
for Performing Urodynamic Studies  
Document History  
 Version  Date Effective  Changes  Rationale for 
Change  
Creation  1.[ADDRESS_652997] Release  
Amendments      
 
This is a premarket clinical  research protocol. This study is conducted in accordance with the 
clinical protoc ol, Good Clinical Practice, and  FDA 21 CFR Parts 50, 812 – Investigational Device 
Exemptions . This study is conducted in accordance with ethical principles that have their origin 
in the Declaration of Helsinki . 
  
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © [ADDRESS_652998] of abbreviations  ................................ ................................ ................................ ............  10 
2 INTRODUCTION  ................................ ................................ ................................ ...................  10 
2.1 Clinical S tudy Summary  ................................ ................................ .............................  10 
2.2 Primary Hypothesis  ................................ ................................ ................................ .... 11 
2.2.1  Primary Safety and Effectiveness Endpoints  ................................ ..........................  12 
3 BACKGROUND  ................................ ................................ ................................ .....................  13 
3.1 Medical Device  ................................ ................................ ................................ ...........  13 
3.2 Prior Literature & Studies  ................................ ................................ ..........................  14 
3.3 Rationale  ................................ ................................ ................................ ....................  15 
4 STUDY OBJECTIVES  ................................ ................................ ................................ ..............  15 
4.1 Primar y Objectives  ................................ ................................ ................................ ..... 15 
4.2 Exploratory Objectives  ................................ ................................ ...............................  16 
4.3 Claims and Intended Performance  ................................ ................................ ............  16 
4.4 Assessment of Risks and Adverse Device Effects  ................................ ......................  16 
5 MEDICAL DEVICE  ................................ ................................ ................................ .................  17 
5.1 Description  ................................ ................................ ................................ .................  17 
5.2 Purpose & Use  ................................ ................................ ................................ ...........  18 
5.3 Summary of Non -Clinical Safety & Performance Data  ................................ ..............  18 
5.4 Summary of Clinical Safety & Performance Data  ................................ ......................  [ADDRESS_652999] Withdrawal  ................................ ................................ ................................ ... 20 
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 8 of 35 
 
7.7 Suspension or Premature Termination  ................................ ................................ ..... 20 
8 MANAGEMENT OF MEDICAL DEVICE  ................................ ................................ ..................  21 
8.1 Description  ................................ ................................ ................................ .................  21 
8.2 Regimen  ................................ ................................ ................................ .....................  22 
8.3 Assignment to Groups  ................................ ................................ ...............................  22 
8.4 Preparation and Handling  ................................ ................................ ..........................  22 
8.5 Packaging and Labelling  ................................ ................................ .............................  22 
8.6 Device Accountability  ................................ ................................ ................................  22 
8.6.1  Laborie to Study Site:  ................................ ................................ ..............................  22 
8.6.2  Study Site Usage:  ................................ ................................ ................................ .... 22 
8.6.3 Study Site to Laborie:  ................................ ................................ ..............................  [ADDRESS_653000] Compliance Monitoring  ................................ ................................ ................  23 
9 ASSESSMENT OF INVESTIGATIONAL DEVICE  ................................ ................................ .......  23 
9.1 Endpoints  ................................ ................................ ................................ ...................  23 
9.2 Methods of Assessment  ................................ ................................ ............................  23 
10 PATIENT SAFETY  ................................ ................................ ................................ ..................  23 
10.1  Definitions  ................................ ................................ ................................ ..................  23 
10.1.1  Adverse Events:  ................................ ................................ ...............................  [ADDRESS_653001]:  ................................ ................................ .....................  24 
10.1.3  Device Deficiency:  ................................ ................................ ............................  24 
10.1.4  Serious Adverse Event:  ................................ ................................ ....................  [ADDRESS_653002] : ................................ .............................  [ADDRESS_653003] ([LOCATION_003]DE):  ................................ .. [ADDRESS_653004] Information  ................................ ................................ ................................ .. 25 
10.6  Follow -Up ................................ ................................ ................................ ...................  25 
11 STUDY PROCEDURE  ................................ ................................ ................................ .............  25 
11.1  Visit Schedule  ................................ ................................ ................................ .............  25 
11.2  Screening for Eligibility  ................................ ................................ ..............................  25 
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 9 of 35 
 
11.3  Part 1 (Informed Consent)  ................................ ................................ .........................  26 
11.4  Part 2 (Urodynamic Clinic Visit)  ................................ ................................ .................  26 
11.5  End of Study (EOS)  ................................ ................................ ................................ ..... 26 
12 STATISTICAL CONSIDERATIONS  ................................ ................................ ...........................  27 
12.1  Primary Safety and effectiveness Endpoints  ................................ .............................  27 
12.1.1  Primary Effectiveness Endpoint  ................................ ................................ .......  27 
12.1.2  Primary Safety Endpoint  ................................ ................................ ..................  27 
12.2  Exploratory Analyses  ................................ ................................ ................................ . 27 
12.3 Sample Size Determination & Power  ................................ ................................ ........  28 
12.4  Randomization / Blinding  ................................ ................................ ..........................  28 
12.5  Analysis Plan  ................................ ................................ ................................ ..............  28 
12.6  Devia tions  ................................ ................................ ................................ ..................  28 
12.7  Early Stoppi[INVESTIGATOR_007]  ................................ ................................ ................................ ............  28 
13 DATA HANDLING & RECORD KEEPI[INVESTIGATOR_1645]  ................................ ................................ ................  [ADDRESS_653005] Access  ................................ ................................ ................................ ..............  28 
13.2  Confi dentiality & Security  ................................ ................................ ..........................  29 
13.3  Data Handling  ................................ ................................ ................................ ............  29 
13.4  Case Report Form (CRF) & Source Documents  ................................ ..........................  [ADDRESS_653006] Stipends or Payments  ................................ ................................ ...................  32 
17.3  Committees  ................................ ................................ ................................ ................  32 
17.4  Study Timetable  ................................ ................................ ................................ .........  32 
18 ETHICS AND REGULATORY APPROVAL  ................................ ................................ ................  32 
19 PUBLICATION POLICY  ................................ ................................ ................................ ..........  33 
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 10 of 35 
 
20 ATTACHMENTS  ................................ ................................ ................................ ....................  33 
20.1  Informed Consent Documents  ................................ ................................ ..................  33 
20.2  Investigator’s Brochure ................................ ................................ ..............................  [ADDRESS_653007] Symptoms  
T-DOC®  Commercial name [CONTACT_206726] -charged catheters  
T-DOC® NXT Next Generation T -DOC® air -charged catheter  
UDS  Urodynamics  
NGM  Next Generation Modular  
PIM Patient Interface Module  
[LOCATION_003] [LOCATION_002] of America  
WFC  Water -Filled Catheter  
Pves  Vesical Pressure (Single sensor bladder catheter)  
Pabd Abdominal Pressure (Abdominal catheter)  
Pura  Urethral Pressure  (Dual sensor bladder catheter)  
 
2 INTRODUCTION  
2.1 Clinical Study Summary  
Number of Sites  1 
Number of Subjects  Minimum 20 and Maximum 40  
Objective  The primary objective of this p remarket  study is to gather clinical data 
as follows:  
• Confirm that the T-DOC®  NXT 7Fr vesical and abdominal 
catheters are safe and effective for measuring urodynamic 
pressure measurements in adults.  
The exploratory  objective of this study is to gather user and patient  
impressions of device performance as foll ows:  
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 11 of 35 
 
• Assess subjective patient feedback regarding the discomfort 
and pain levels  
• Assess user impressions of device performances by [CONTACT_506210]: ease of use, ease of 
insertion, presence of artefacts, presence of cough s/valsalva 
response , measurements and tracings of urethral pressure 
profiles, stability of the tracing, perceived time savings, ease 
of voiding around catheter, presence of use errors , and 
overall satisfaction  
Inclusion criteria  - Male and Female (Adult age 21+)  
- Patients with clinical indication for urodynamics (UDS) testing, for 
any medically necessary reason as per the physician.     
Exclusion criteria  - Patients who suffer from bladder infections (not including 
patients with asymptomatic bacter iuria) 
- Patients who are pregnant  
- Patients with recent (less than 2 weeks) pelvic floor surgery  
- Patients who require the use of a suprapubic catheter  
- Patients with significant cognitive deficiency that prevent the 
patient from giving informed consent  
Anticipated Study duration  The proposed recruitment phase following site initiation is 8 weeks 
(first subject  in to last subject  out).  
 
Patient s will come to the clinic for one visit, th e UDS procedure, 
where data pertaining to the safety, efficacy and usability aspects of 
catheter will be collected.    
 
Test duration may be slightly longer than a standard test while 
assessment of the study materials is being made, and so discomfort 
and inconvenience associated with an extended test d uration may 
occur.  
Follow -up No patient follow -up different than a usual UDS study will be 
required .  There is no required follow -up for the study unless there is 
an adverse event.  
Study end point  Once the minimum subject recruitment goal is met, the spo nsor will 
be informed.  The s ite will have an option to continue recruitment 
until the maximum is reached, or the [ADDRESS_653008].    
There will be a site monitoring visit (s) as per the monitoring plan  
2.2 Primary Hypothesis  
The primary objective of this p remarket  study is to gather clinical data as follows:  
• Confirm that the T -DOC ® NXT vesical and abdominal catheters are safe and effective for 
measuring urodynamic (UDS)  pressure measurements in adults.  
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 12 of 35 
 
2.2.1 Primary Safety and Effectiveness Endpoints  
Primary Effectiveness Endpoint  
The primary effectiveness endpoint is a binary clinician response after each UDS  study using the 
T-DOC® NXT Catheter to determine whether the abilit y to measure UDS  pressure was clinically 
adequate (success) or inadequate (failure). The primary effectiveness hypothesis is a 
comparison of the lower bound for the estimate of the success rate to a minimally acceptable 
target value of 75%:  
H0: Effectivene ss Success Rate is ≤ 75%  
versus  
HA: Effectiveness Success Rate is > 75%  
This hypothesis will be evaluated by [CONTACT_222691] 1 -sided 95% Clopper -
Pearson confidence interval to 75%. The null hypothesis will be rejected if the lower limit  of the 
1-sided 95% Clopper -Pearson confidence interval is > 75%, which indicates that a rate ≤75% 
would be inconsistent with the trial findings.  
Primary Safety Endpoint  
The primary safety endpoint is a binary clinician response after each UDS  study using the T -
DOC® NXT Catheter to determine  whether the safety of the device was clinically adequate 
(success) or inadequate (failure). The primary safety hypothesis is a comparison of the lower 
bound for the estimate  of the success rate to a minimally acceptable  target value of 75%:  
H0: Safety Success Rate is ≤ 75%  
versus  
HA: Safety Success Rate is > 75%  
This hypothesis will be evaluated by [CONTACT_222691] 1 -sided 95% Clopper -
Pearson confidence interval to 75%. The null hypothesis will be rejected if the lower limit of the 
1-sided 95% Clopper -Pearson confidence interval is > 75%, which ind icates that a rate ≤75% 
would be inconsistent with the trial findings.   
 
2.4  Exploratory Analyses  
The following exploratory objectives of this study are to gather data on the following:  
• Assess subjective patient feedback regarding the discomfort and pain  levels  
• Assess user impressions of device performances based on their individual experi ence 
with existing ACC  catheters  by [CONTACT_506211]: ease of 
use, ease of insertion, presence of artefacts, presence of cough s/valsalva res ponse , 
measurements and tracings of urethral pressure profiles, stability of the tracing, 
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 13 of 35 
 
perceived time savings, ease of voiding around catheter, presence of use errors , and 
overall satisfaction   
3 BACKGROUND  
3.1 Medical  Device  
Initially, water -filled catheters ( WFC ) were the only UDS  catheter technology available and only 
intrav esical pressure was assessed ( Perez & Webster, 1992). However, with the demand for 
different ways to better assess LUT dysfunction, multiple catheters types have be en developed.  
Currently, there are four different UDS catheter -based technologies available: WFC, air-charged 
catheters ( ACC), microtip catheters, and fiberoptic catheters. It is generally known that m inimal 
tracings artefacts and non -physiological change s in pressure are desired for a reliable UDS 
tracing  (Couri et al., 2017). It has been noted that ACC are less likely to be influenced by 
[CONTACT_206697], thus decreasing the occurrence of artefacts (Cooper  et al., 2011, Gammie et al., 
2014). The Sponsor views this as a great advantage in the adult  population  since  movement 
artefact can be a common issue affecting interpretation of the UDS  tracing  (Cooper  et al., 
2011 ). The study is designed to test a new generation of UDS equipment and ACC cat heters.  
The existing T-DOC® [ADDRESS_653009] introduced to the market in the early 
2000s. The design comprises a patent -protected catheter balloon charging mechan ism 
(US6447462/EP1255485) that facilitates the pressure transfer medium for recording UDS  
pressure and detection of UDS  events. The device is provided as a sterile, single -use catheter.  
 
 
 
 
 
 
 
 
 
The catheters under review in this clinical investigation are the next iteration of the T-DOC®  G1 
catheters called T-DOC®  NXT, and are intended for use on adult populations for measuring UDS  
pressures.    
There are two T-DOC®  NXT catheter configurations under assessment. The first will be a 
combination of a single sensor vesical (bladder) catheter, and an abdominal/rectal catheter.  
The second configurati on will include a dual sensor bladder (urethral) catheter and an 
abdominal/rectal catheter.  T-DOC®  NXT catheters have  gone through extensive design changes 
to provide improved performance and efficiency to our customers. Furthermore, the design has 
been im proved with a new catheter -connector for easier connectivity, a modified balloon , and 
increased catheter length for better performance . Furthermore, the new design offers an easier 

 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © [ADDRESS_653010] mechanism, which pro vides an 
audible and tactile feedback not present in our existing line of T -DOC ® G1 catheters  
Table 1.  Dimensional changes and operational data comparison between  existing T-DOC®  G1 
catheters and T-DOC®  NXT.  
 Existing T-DOC® G1  Proposed T -DOC® NXT  
 
   
 
 
  
  
 
Pves Balloon Sensor Location  1” from the tip  1” from the tip  
Pabd Balloon Sensor Location  1” from the tip  1” from the tip  
Pura Balloon  Sensor Location (If 
Applicable)  2.36” from Pves  2.36” from Pves  
 
 
  
  
 
Catheter Length  23.5”  Abdominal: 31.4"  
Single /Dual  sensor  urethral 
catheter : 37.4"  
 
Flow Rate Specification  Maximum 70mL/min  70 mL / min  
Sensor Balloon Measurement 
Error  Maximum 4.0% of applied 
pressure at 0 – 250 cmH 20 
(system level)  Maximum 4.0% of applied 
pressure at 0 –  250 cmH 20 
(system level) *   
Operational Pressure Range  0 to 250 cmH 20 0 to 250 cmH 20 
*Design feasibility test results indicate <3% balloon measurement error  
3.2 Prior Literature & Studies  
The T -DOC® ACCs  have been regarded as simple to use, easy to insert, set -up, and zero  to 
atmospheric pressure (Internal  Doc #PD-TR-151-01).  This has been supported by [CONTACT_506212] -charged catheters are gaining popularity due to t heir simple 
handling and set-up (Chapple, MacDiarmid & Patel, 2009) .  Several studies have been published 
that examine the accuracy and behaviour of ACCs, both in non -clinical (Cooper et al ., 2011, 

 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 15 of 35 
 
Couri et al., 2007 ), and clinical ( T. McKinney, 2015, Gammie et al., 2016, Digesu  et al. , 2014) 
settings .  Since this is a new investigational device, there is no prior literature examining the 
safety and effectiveness of the T-DOC®  NXT catheter i n patients.   
 
Please refer to Section 5 of the Investigator Brochure ( TDOC -NXT-01-IB) for  a more detailed 
review of the available published literature.  
3.3 Rationale  
The next generation T-DOC®  catheter  (T-DOC®  NXT)  is based on our previous  Air-Charged 
Catheter (ACC) technology, that has under gone design changes to provide improved 
performance and efficiency to our customers. The design has been improved with a new 
catheter -connector for easier connectivity, a modifi ed balloon and increased catheter length 
for better performance. Since  T-DOC®  NXT is based on an existing design, there is published 
data supporting the safety, performance and usability of the  principle aspects of the design . T-
DOC®  ACCs have been on the market over 10 years (>6MM sold catheters) and ha ve collected 
significant amount of data in adults.  However, due to the design changes, further evidence is 
required to confirm the safety and effectiveness of the next generation catheter prior to market 
release. The aim of this pre-market study is to collect data of the catheter s’ performance and 
confirm they are safe and effective for UDS . Furthermore, the new design offers an easy and 
effective workflow due to the new catheter -connect mechanism, which provides an audible and 
tactile feedback not present in the existing line of T -DOC ® catheters.   Summative usability 
testing will be conducted in a  simulated environment, and will be confirmed in this pre -market 
study. A limitation to this study is that it will be conducted with the Aquarius NGM unit with a 
modified cable to allow the catheters to connect with the new catheter -connect system. This 
modification is necessary because the NXT UDS machine with new T-DOC®  NXT Patient 
Interface Module (PIM) will not be available. This study will gather  data to support concurrent 
design validation activities while establishing clinical safety and effectiveness of the device in 
the adult population.   
Finally, there will be no con trol arm, blinding, or treatment/intervention component to this 
study.  This is based on the trial design and the fact that this is a non -comparative study ; 
inclusion of a sham or placebo is not feasible nor necessary, and the device under evaluation is 
not a treatment or intervention.   
For the purposes of this study, decisions regarding timing for prescribing UDS  testing will be at 
the discretion of the Investigators.  
4 STUDY OBJECTIVES  
4.1 Primary Objectives  
The primary objective of this premarket  study is to gather clinical data as follows:  
• Confirm  that the T-DOC®  NXT 7Fr vesical and abdominal catheters a re safe and effective 
for measuring UDS  pressure measurements in adults.  
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 16 of 35 
 
4.2 Exploratory Objectives  
The exploratory objective of this study is to gat her user impressions of device performance as 
follows:  
• Assess subjective patient feedback regarding the discomfort and pain levels  
• Assess user impressions of device performances based on their individual experi ence 
with existing ACC catheters evaluating the following subjective measures: ease of use, 
ease of insertion, presence of artefacts,  presence of coughs /Valsalva response , 
measurements and tracings of urethral pressure profiles, stability of the  tracing, 
perc eived time savings, ease of voiding around catheter, presence of use errors and 
overall satisfaction  
4.3 Claims and Intended Performance   
• The T-DOC ® NXT catheter causes minimal discomfort during insertion, during the test, 
and removal  
• Adverse Event Claims as p er results  
• Subjective claim s: 
o The T -DOC ® NXT catheters are safe and effective for use on adult patients  
o The T -DOC ® NXT catheters are easy to use  
o The T -DOC ® NXT catheters are easy to set -up / zero  
o The T -DOC ® NXT catheters are easy to insert  
o The T -DOC ® NXT catheters have consistent/stable tracings  
o The T -DOC ® NXT catheter has adequate subtracted pressures  
 
4.[ADDRESS_653011] duration  may occur.    
UDS  testing exposes subjects to risks of urethral instrumentation which can result in infection, 
urethral trauma and pain (Winters et al.  2012).  Other  risks can include transient discomfort 
during or following the procedure, transient dysuria or bleeding  (hematuria) following the 
procedure, or urinary tract infection , which  occurs in 2 -4% of subjects ( Chapple, MacDiarmid & 
Patel, 2009).   
In conclusion, the overall residual risks associated with the use of T -DOC® NXT catheters with in 
this study set -up, are acceptable when weighed against the benefits , and are no different than 
the risks when using other UDS catheter technologies .  The sponsor team has also established 
that patients  are subjected to no more than minimal risk since an IDE is not required for this 
study  (Ref: TDOC -NXT-01 - Risk Determination).   Lastly , UDS is a widely -performed procedure 
on subjects requiring specialized management for urinary incontinence/retention problems, as 
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 17 of 35 
 
recommended by [CONTACT_206700] (Abrams et al., 2013 ), and is useful in characterizing LUT function, 
identifying causes of symptoms and quantifying related pathophysiological processes ( Rosier 
PF., 201 3). Thus, the clinician must weigh the risks and benefits  as to whether the UDS test 
offers additional diag nostic value beyond symptom assessment, physical examination and other 
diagnostic testing (Winters et al.,  2012).     
5 MEDICAL DEVICE  
5.1 Description  
The catheters used in this study will be design verified, sterilized and appropriately labelled 
before the clinical investigation can begin.    
The catheter device models to be evaluated as part of this study include:  
1. T-DOC®  NXT vesical single sensor cath eter ( blue)  
2. T-DOC®  NXT abdominal single sensor catheters ( red) 
3. T-DOC®  NXT Vesicle , dual sensor catheter available for optional urethral 
measurement studies (blue and yellow)  
  
Traceability of investigational study materials will be maintained via  the Inven tory Control Log 
(Q905 -FRM -17). Any remaining investigational material stock after study close -out will be 
returned to the study sponsor at the sponsors’ expense.    
The T -DOC® NXT catheters are manufactured using equivalent materials to the existing T -DOC® 
G1 catheters , and are verif ied biocompatible in 
accordance with the standards EN ISO [ZIP_CODE] -5 and -10 and -18 – Biological evaluation of 
medical devices.   
None of the materials being used in this study contain biologically active substances or 
pharmacological agents.  
From a Regulat ory standpoint, the following medical device classification rules apply  in Europe, 
the [LOCATION_002] and Canada, respectively :  
 
For the European Union, Class IIa  
For the [LOCATION_002], Class II as per FDA  
For Canada, Class II  as per Health Canada Medical Device Regulations  
 

 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 18 of 35 
 
5.2 Purpose & Use  
Intended Use:  The Air-charged Urodynamic Catheters are intended for measuring Urodynamic  
pressures. The Air-charged Urodynamic  Catheters are intended to be connected to 
Urodynamics  Analyzer systems using a reusable electronic  component . 
Indications for Use:  The UDS  Catheters are sterile and intended for single use on adult patient 
population r equiring UDS  pressure monitoring through the measurement of bladder, urethral , 
and rectal  (or vaginal)  pressures.   
5.3 Summary of Non -Clinical Safety & Performance Data  
The T-DOC® NXT family of UDS  catheters has been  tested per ISO [ADDRESS_653012] meet all 
biocompatibility requirements for acute tissue contact[CONTACT_506213],  
Sensitization, and Irritation.   Furthermore, design verification studies will be undertaken to 
verify that Level 2 design requirements are met.  Please refer to the Investigator Brochure for 
further details.  
5.4 Summary of Clinical Safety & Performance Data  
Please refer to Section 5 of the Investigator Brochure (TDOC -NXT-01-IB) for detailed review of 
relevant previous clinical safety and performance data.  In all literature presented , the T -DOC® 
air-charged catheters are safe and  effective for measuring UDS  pressures further justifying the 
study rationale.   
 
5.[ADDRESS_653013]  benefit for participating other than to gather objective 
evidence of T-DOC® NXT 7 Fr ACC  clinical use.   Please r efer also to Section 4.5 above 
(Assessment of Risks and Adverse Device Effects) , and Section 6 of the Investigator Brochure 
(TDOC -NXT-01-IB). 
 
The sponsor has also established that patients are subjected to no more than minimal risk since 
an IDE is not req uired for this study (Ref: TDOC -NXT-01 - Risk Determination).   Lastly, UDS  is 
already a widely performed procedure on subjects requiring specialized management for 
urinary incontinence issues, as recommended by [CONTACT_206700] (Abrams et al., 2013), and is useful in 
characterizing LUT function, identifying causes of symptoms and quantifying related 
pathophysiological processes ( Rosier P.F. , 201 3).  In conclusion, the overall residual risks 
associated with the use of T -DOC® NXT catheters with in this study set -up, are acceptable when 
weighed against the benefits.   
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © [ADDRESS_653014] s will undergo a 
conventional UDS  study that will be conducted according to Good UDS  Practices (Rosier et al ., 
2016).   Subject data including age, medical history, height, weight, adverse events during or 
immediately following the test, catheter insertion depth etc., will be collected on each  patient ’s 
CRF.  There will be no control arm, blinding, or treatment/intervention component to this 
study.   
 
The following steps  gives a high -level overview of the study design and subject flow -through 
based  on number  of patients enrolled:  
• Adult patients  are referred for UDS  testing  
• Patient are approached to enrol  in the study during their UDS  visit and give informed 
consent  
• Urodynamic testing is conducted,  and case report forms are completed  
• Adverse events are followed for closure  
6.[ADDRESS_653015]’s participation is one clinic visit to receive their already 
prescribed UDS  test.   Once ethics board approval is received, site training and initiation is 
expected to take 1-[ADDRESS_653016]  is recruited.  
7 PATIENT SELECTION  
7.1 Inclusion Criteria  
• Male and Female (Adult age 21+)  
• Patients who are scheduled  and indicated  for UDS  testing, for any medically necessary 
reason as per the physician .     
7.2 Exclusion Criteria  
• Patients who suffer from bladder infections (not including patients with asymptomatic 
bacter iuria)  
• Patients who are pregnant  
• Patients w ith recent (less than 2 weeks) pelvic floor  surgery  
• Patients who require the use of a suprapubic catheter  
• Patients with significant cognitive deficiency that prevent the patient from giving informed 
consent  
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © [ADDRESS_653017] group  is not a vulnerable population  
7.4 Recruitment Plans  
The tar get enrolment is a minimum of 20 patients (maximum 40) . 
Subjects who are visiting the UDS  clinic for their medically -indicated UDS  test will be 
approached regarding participation in this  study.   It is estim ated that recruitment should take 
approximately [ADDRESS_653018]  signs the informed consent, this will be treated as the point of 
enrolment.    
7.5 Informed Consent  
The Investigator (according to applicable regulatory requirements), or a person designated by 
[CONTACT_737], and under the Investigator's responsib ility, should fully inform the subject  of 
all pertinent aspects of th is clinical tria l, including the written information giving a favourable 
opi[INVESTIGATOR_1649] b y the IRB .  New information regarding  the study will be provided to the subject by [CONTACT_506214].  
Prior to a subject ’s participation in the clinical trial, the written Informed Consent Form should 
be signed, name [CONTACT_56535] [CONTACT_506215] .  A copy of the signed and dated written Informed  Consent will 
be provided to the subject .  The date of the informed consent should be recorded on the 
subject’s CRF.   
The Informed Consent Form  used by [CONTACT_206703] 's informed 
consent must be reviewed and approved by [CONTACT_506216]/favourable opi[INVESTIGATOR_1649].  
The study sponsor does not foresee any circumstances where emergency enrolment would 
occur due to the device indication (it is not used in emergency situations), and the fact t hat 
patients being recruited are attending their UDS  appointment as a pre -scheduled visit.  
7.[ADDRESS_653019]’s 
participation (see below). The I nvestigator will notify the sponsor when a subject is withdrawn 
from the study (and if possible why), and this will be recorded on the subject’s CRF and 
withdrawal form.   Subjects who withdraw from the trial will be allowed to be replaced by  
[CONTACT_99419].   
7.7 Suspension or Premature Termination  
The study may be terminated prematurely if the Sponsor  or the Investigator feel that the 
equipment is not producing results as expected which could be  due to inappropriate operator 
handling or faulty equip ment.  The Investigator and/or s ponsor would determine termination 
by [CONTACT_206705] , design defects , evidence of noncompliance, or serious 
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 21 of 35 
 
and/or continuing noncompliance  which could  affect any of subject safety, device performance 
or integrity of study data .  
8 MANAGEMENT OF MEDICAL DEVICE  
8.1 Description  
The following devices and equipment will be required for each patient.  Those indicated by 
[CONTACT_356012]  (*) are to be sourced and provided by [CONTACT_779]:  
• Laborie UDS  equipment  already in use  
• Computer/laptop with Laborie UDS -120 UDS  software already loaded and in use by [CONTACT_204816] 
• Infusion transdu cer (optional ) 
• Uroflowmetry/Urocap device configured with the UDS  equipment  and computer for 
pressure -flow studies, already in use by [CONTACT_25733] (optional)  
• T-DOC® transducer backwards compatibility cables:  
o Pabd (red) – Abdominal channel reusable cable  
o Pves  (blue ) – Bladder channel reusable cable   
o Pura (yellow) - Urethral channel reusable cable (optional)  
• One (1) air -charged T -DOC®  NXT abdominal single sensor catheter per subject   
• One (1) air -charged T -DOC® NXT single sensor catheter or one (1) air-charged T -DOC® 
NXT dual  sensor catheter  per subject  
• EMG cable (optional component at the discretion of the site)  
• EMG patches (optional component at the discretion of the site)  
• Laborie UDS  pump tub ing infusion line per subject ( must be Laborie part num ber: 
TUB500)  
• 1000 mL beaker * (whatever is currently in use at the site)  (optional)  
• Weight of 500g provided by [CONTACT_206707]  (optional?)  
• One ( 1) sterile  saline bag per subject*  
• Tape *  
• Lubricant * 
• Gloves * 
• Any other supplies deemed necessary for conducting a UDS  study* 
 
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 22 of 35 
 
The study agreement will further specify the equipment and disposables that will be required 
and provided by [CONTACT_206707].  
8.2 Regimen  
N/A – there is no treatment regimen required as part of this study.  
8.3 Assignment to Groups  
No stratification of subjects will be utilized based on study design.  
8.4 Preparation and Handling  
The Urodynamic system and air -charged catheters will be prepared, and maintained by [CONTACT_24201].   
8.5 Packaging and Labelling  
Investigational device labelling will appear on all investigational materials under FDA 21 CRF 
Subpart 812.5.  A copy of the investigational label is shown the Investigator’s Brochure.   
8.[ADDRESS_653020] be recorded using the device LOT number on 
the s ubjects CRF form.   
8.6.1 Laborie to Study Site:  
All investigational devices or equipment transferred between Laborie and the study site must 
be recorded through  the Inventory Control Log.  This includes postal deliveries and any 
deliveries made in person by [CONTACT_506217].  Any equipment or devices that are not used and are 
returned to Laborie must be recorded on the Inventory Control Log as well .  It is Laborie’s  
responsibility to ensure that all inventory both at Laborie and the study site correlate.   All 
investigati onal device accountability will be recorded through the Inventory Control Form .  
8.6.2 Study Site Usage:  
All devices used directly for testing subject samples must be recorded on the Inventory Control 
Form.  All devices used by [CONTACT_506218].  This includes any devices used for 
training or demonstration or any devices which are noted to be defective when opened.  
8.6.3 Study Site to Laborie:  
Any equipment or dev ices that are not used and are returned to Laborie must be recorded on 
the Inventory Control Form.  
When the devices have been received by [CONTACT_206707], it is Laborie’s responsibility to ensure that all 
inventory control forms both at Laborie and the study site  correlate.  
8.7 Concomitant Treatment  
Not applicable in this study   
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © [ADDRESS_653021] Compliance Monitoring  
Not applicable in this study.  
9 ASSESSMENT OF INVESTIGATIONAL DEVICE  
9.1 Endpoints  
OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINTS  
Primary    
To confirm the T-DOC®  NXT vesical 
and abdominal catheters are a safe 
and effective means of measuring 
UDS  pressure in adults.  The primary endpoint will be 
measured by [CONTACT_506219].  The 
clinician will indicate whether the T -
DOC® NXT vesical and abdominal 
catheters are safe and effective for 
measuring UDS  pressure in at least  [ADDRESS_653022] that can 
establish the safety and 
effectiveness, it is 
justified to ob tain 
clinician feedback via  a 
binary  response 
whether the device 
was safe and/or 
effective for measuring 
UDS  pressure.   
 
9.2 Methods of Assessment  
A T-DOC ® NXT air-charged catheter will be used to assess and record bladder and abdominal 
pressures which are in turn used by [CONTACT_506220].   These measurements 
will be recorded using a LABORIE UDS  system.   The resulting interpretations regardi ng safety, 
effectiveness, and usability will be made by [CONTACT_506221]’s case.   
All study outcome data captured will be compi[INVESTIGATOR_506207].    
10 PATIENT SAFETY  
10.1 Definitions  
 
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 24 of 35 
 
10.1.1  Adverse Events:  
Any untoward medical occurrence in a subject, whether or not related to the investigational 
medical device.  
10.1.[ADDRESS_653023]:   
Any adverse event rel ated to the use of a n investigation medical device.  
10.1.3  Device Deficiency :  
Inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety 
or performance  
10.1.4  Serious Adverse Event:  
An adverse event that:  
1. Led to a death;  
2. Led to a serious deterioration in health of a patient, user, or others that:  
a. Results in a life-threatening  illness or injury;  
b. Results in a permanent impairment of a body structure or body function;  
c. Requires in patient hospi[INVESTIGATOR_1081];  
d. Results in medical or surgical intervention to prevent life -threatening illness or 
injury or permanent impairment to body structure or a body function;  
3. Led to foetal  distress, foetal  death or a congenital abnormali ty/birth defect.  
10.1.[ADDRESS_653024]:  
Any serious adverse effect on health or safety or any life -threatening problem or death caused 
by, or associated w ith, a device, if that effect, problem, or death was not previously identified in 
natur e, severity, or degree of incidence in the investigation protocol or application, or any other 
unanticipated serious problem associated with a device that relates to the rights, safety, or 
welfare of subjects.  
10.1.[ADDRESS_653025] (U SADE):  
Serious adverse device effect which by [CONTACT_6073], incidence, severity or outcome has not been 
identified in the current version of the risk analysis report.  
10.[ADDRESS_653026] ed on the CRF . 
10.3 Reporting  
All serious adverse events and unanticipated adverse device effects occurring during the 
investigation will be reported as soon as possible, but no later than 10 working days after the 
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 25 of 35 
 
Investiga tor/Laborie first learns of the effect. This information will be submitted to 
Laborie/investigator and the IRB.  
10.[ADDRESS_653027]:  
 
 
 
 
10.[ADDRESS_653028] notify Laborie of the outcome of the follow -up.  The study 
safety endpoint will be measured by [CONTACT_506222].   
11 STUDY PROCEDURE  
11.1 Visit Schedule  
 
Evaluation  Screening & Clinic Visit  
Part 1*  Part [ADDRESS_653029] any Adverse Events   X 
Complete CRF   X 
*Part 1 and Part 2 may be  combined into 1 visit  
11.2 Screening for Eligibility  
Subjects may be screened for eligibility for this study by [CONTACT_206713].  No 
special testing is required in order to determine eligibility.   

 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 26 of 35 
 
 
11.3 Part 1  (Informed Consent)   
1. Conduct Informed Consent discussion with the subject and sign  
 
11.4 Part 2 (Urodynamic Clinic Visit)  
1. Determine if the subject is eligible for this study.  
2. Conduct Informed Consent discussion with the subject and sign.  
3. Collect medical history and record  in case report form ( TDOC -NXT-01- CRF2).  
4. Collect and record other patient details as required on TDOC -NXT-01- CRF1  
[weight (lbs), height (‘,”), date of birth, sex, etc].  
5. Site personnel will explain what will happen during the UDS  test to the 
subject/parent or caregiver.   
6. Site personnel will prepare UDS  equipment, study materials, other sterile 
disposables and supplies as required for the UDS  study and record catheter lot 
number information on TDOC -NXT-01- CRF1 . 
7. Follow the investigational device instructions for use for placing the catheters.    
Record all the necessary data on TDOC -NXT-01- CRF1 .   
8. Conduct UDS  study according to ICS Good UDS  Practice recommendations, 
includ ing regular cough checking to ensure good pressure transmission and 
catheter positioning wherever possible (Rosier et al.,  2016).  Record all the 
necessary data on TDOC -NXT-01- CRF1.  
9. Site personnel to ask patients to answer questions on urodynamic experienc e 
and record all data on  TDOC -NXT-01- CRF4 . 
10. After completing a day of urodynamics, the user is to fill out a questionnaire and 
record all necessary data on TDOC -NXT-01- CRF3 . 
 
 
NOTE: If an adverse event occurs during this study, any follow -up intervention prescribed is at 
the discretion of the Investigator.  This information should also be recor ded on the subje ct’s 
CRF ( TDOC -NXT-01- CRF1 -) and the AE form  (TDOC -NXT-01- CRF5 ).  
11.5 End of  Study (EOS)  
At the conclusion of the UDS  test, the subject is no longer required to undergo any further 
study -related procedures.  
Once a site has completed its target recruitment, the sponsor (Laborie) will schedule a time to 
close -out the site, either in person or by [CONTACT_506223] .  All study related 
files will be collected and reviewed for completeness.  The EOS is considered the point when all 
subjects have been followed -up and data collection completed.   
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 27 of 35 
 
12 STATISTICAL CONSIDERATIONS  
12.1 Primary Safety and effectiveness Endpo ints 
12.1.1  Primary Effectiveness Endpoint  
The primary effectiveness endpoint is a binary clinician response after each UDS  study using the 
T-DOC® NXT Catheter to determine whether the ability to measure UDS  pressure was clinically 
adequate (success) or inadequat e (failure). The primary effectiveness hypothesis is a 
comparison of the lower bound for the estimate of the success rate to a minimally acceptable 
target value of 75%:  
H0: Effectiveness Success Rate is ≤ 75%  
versus  
HA: Effectiveness Success Rate is > 75%  
This hypothesis will be evaluated by [CONTACT_222691] 1 -sided 95% Clopper -
Pearson confidence interval to 75%. The null hypothesis will be rejected if the lower limit of the 
1-sided 95% Clopper -Pearson confidence interval is > 75%, which indicates that a rate ≤75% 
would be inconsistent with the trial findings.  
12.1.2   Primary Safety Endpoint  
The primary safety endpoint is a binary clinician response after each UDS  study using the T -
DOC® NXT Catheter to determine whether the safety of the device was clinically adequate 
(success) or inadequate (failure). The primary safety hypothesis is a comparison of the lower 
bound for the estimate of the success rate to a minimal ly acceptable target value of 75%:  
H0: Safety Success Rate is ≤ 75%  
versus  
HA: Safety Success Rate is > 75%  
This hypothesis will be evaluated by [CONTACT_222691] 1 -sided 97.5% Clopper -
Pearson confidence interval to 75%. The null hypothes is will be rejected if the lower limit of the 
1-sided 97.5% Clopper -Pearson confidence interval is > 75%, which indicates that a rate ≤75% 
would be inconsistent with the trial findings.  
12.2 Exploratory Analyses  
• Assess subjective patient feedback regarding the discomfort and pain levels  
• Assess user impressions of device performances  based on their individual experience 
with existing ACC catheters  by [CONTACT_506211]: ease of 
use, ease of insertion, presence of artefacts, presence of cough /valsalva response , 
measurements and tracings of urethral pressure profiles, stability of the tracing, 
perceived time savings, ease of voiding around catheter, presence of use errors and 
overall satisfa ction  
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 28 of 35 
 
12.3 Sample Size Determination & Power  
The null hypotheses for the primary safety and the primary effectiveness endpoints are 
designed to rule out success rates ≤ 75%. There will be no type I error adjustment for 
simultaneous testing of these endpoints wi thin the same trial. Based on clinical judgement and 
previous testing, the true success rate for both safety and efficacy is assumed to exceed 95%. 
Thus, the power calculation is identical for the safety and effectiveness endpoints, and a true 
success rate  of 96% is assumed for each endpoint.  
Analysis of 20 subjects would provide 81% power to rule out a success rate ≤ 75% when the 
true success rate is assumed to be 96%, based on a [ADDRESS_653030] with type I error rate of 5%.  
This study requires a minimum of 20 subjects to ensure adequate power, but the final sample 
size will be based on site enrolment capabilities. If 30 subjects or 40 subjects are enrolled, the 
power to rule out a success rate ≤ 75% will be 96% and 99%, respectively  (Fleiss , J.L. et al., 
2003). 
12.4 Randomization / Blinding  
Randomization and/or blinding is not utilized in this study based on study design.  
12.[ADDRESS_653031] design meets the user requirements.   
There are  currently  no criteria for stoppi[INVESTIGATOR_206683], however 
please refer to Section 7.7 for details about suspension or premature termination.   
13 DATA HANDLING & RECORD KEEPI[INVESTIGATOR_1645]  
13.[ADDRESS_653032] Access  
The Investigator/Institution will permit trial -relat ed monitoring, audits, IRB review, and 
regulatory inspections by [CONTACT_206717]/documents as needed.  
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 29 of 35 
 
13.2 Confidentiality & Security  
All information disclosed or provided by [CONTACT_1034] (or any company/institution acting on 
their be half), or produced during the study , including, but not limited to, the  Study  Protocol, 
the CRFs, the Instructions for Use and the results  obtained  during the course of the study , is 
confidential.  The Investigator or any person  under his/her authority agrees to undertake to 
keep confidential and not to disclose the  information to any third party without the prior 
written approval of the Sponsor.  
However, the submission of this Study  Protocol and other necessary documentation to the 
Ethics Comm ittee ( IRB) is expressly permitted, the IRB members having the same obligation of 
confidentiality.  
The Sub -Investigators , if employed, shall be bound by [CONTACT_506224]. 
The Investigator shall inform the Sub -Investigators of the con fidential nature of the Usability 
Study . 
The Investigator and the Sub -Investigators shall use  the information solely for the purposes of 
the Study , to the exclusion of any use for their own or for a third  party's account.  
All data to Laborie will be confid ential and all subject identifiers will be blacked out before 
being sent to Laborie. Documents will be kept in a secure location and all digital information 
will be kept following HIPAA and local government regulations.  
13.[ADDRESS_653033] of individuals will be maintained who are authorized to make any changes to the data. 
Data will be reviewed by [CONTACT_1034] (outside of monitoring personnel), and requests for 
clarification and/or corrections will be made through the monitor. Once the review is 
conducted,  the database will be considered clean and ready for analysis. Missing values will 
remain missing, i.e. no attempt will be made to input missing values and only observed values 
will be used in data analyses and presentations.  
13.4 Case Report Form (CRF) & Sourc e Documents  
All study staff will be trained on the protocol requirements and questionnaire completion. It is 
the responsibility of the Investigator to maintain adequate and accurate questionnaires and 
CRFs designed by [CONTACT_506225].  All questionnaires and CRFs should be completed in their entirety in a neat, 
legible manner to ensure accurate integration of data. Should a correction be made, the 
information to be modified must not b e overwritten.  The corrected information will be 
transcribed by [CONTACT_206718].  Source document worksheets for 
recording data will be created as agreed upon by [CONTACT_506226].  Data from 
the source documen ts should be entered into the CRF after each subject ’s visit.  The 
anonymized UDS  data files (DTA files) requested by [CONTACT_206720], to confirm the 
quality of the study .  A unique subject code will  be assigned to each subject  based on the si te 
number (100) and sequential subject number (i.e. 100 -001). The investigator is responsible for 
maintaining subject  identifying information.   CRF’s will be treated as source data in the event 
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © [ADDRESS_653034] (and  no source document worksheet is 
utilized for that data point).   
13.[ADDRESS_653035] Retention  
An investigator or sponsor shall maintain the records required by 21 CFR Part 812.140 during 
the investigation and for a period of 2 years after the latter of the following two dates: The date 
on which the investigation is terminated or completed, or the date that the records are no 
longer required for purposes of supporting a premarket approval application or a notice of 
completion of a product development protocol. The Inve stigator must maintain confidential all 
study documentation, and take measures to prevent accidental or premature destruction of 
these documents. All essential documents from the Investigator will be kept in the Investigator 
binder.  All sponsor essential documents will be kept in the study master file. The investigator 
and sponsor shall also maintain a record of their location of the respective essential documents. 
If the Investigator's personal situation is such that archiving can no longer be ensured by  
[CONTACT_12552]/her, the Investigator shall inform the Sponsor and the relevant records shall be  transferred 
to a mutually agreed upon designee.  
13.6 Performance Monitoring  
Monitors will periodically check questionnaire data to ensure all fields are entered as far as 
possi ble and inquire as to whether any usability issues are being encountered as the study 
progresses.  
14 MONITORING, AUDITING, AND INSPECTING  
14.1 Study Monitoring Plan  
The Investigator agrees to provide reliable and accurate data , and all information  requested by 
[CONTACT_4690] (with the help of any questionnaire, other appropriate  instrument s) in an 
attributable, legible, contemptuous, original, accurate, and complete form  according to the 
instructions provided and to ensure direct access to source  documents to Sponsor 
representatives.  Any changes to the soured data shall be traceable and not obscure the original 
entry.  
The Sponsor of this Study  is responsible to Health Authorities for taking all  reasonable steps to 
ensure the proper conduct of this study p rotocol with regards to ethics,  protocol  compliance, 
integrity and validity of the data recorded on  the CRF and questionnaires . Thus, the main duty 
of the Monitoring Team is to help the  Investigator and the Sponsor maintain a high level of 
ethical, scientific, technical and  regulatory qua lity in all aspects of the study .  
At regular intervals during the study , the site will be contact[INVESTIGATOR_530], through  monitoring visits, 
letters or telephone calls, by a representative of the Monitoring Team to  review study progress, 
Investigator and subject  compliance with study protocol requirements, and any emergent 
problems. The monitoring plan will describe the frequency, extent, and nature of monitoring.  
 
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © [ADDRESS_653036] access to his/her study records 
for review, being understood that these personnel  are bound by [CONTACT_56520], and as 
such will not disclose any personal identity or personal medical information.  
 
The Investigator  will make every effort to help with the performance of the inspections, giving 
access to all necessary facilities, data, and documents.  
 
As soon as the Investigator is notified of a future inspection by [CONTACT_56521], he will inform 
the Sponsor and aut horize the Sponsor to participate in this inspection.  
 
The confidentiality of the data verified and the protection of the subjects should be respected 
during these inspections.  
  
Any result and information arising from the inspections by [CONTACT_506227]. The Investigator shall take 
appropriate measures required by [CONTACT_206721].  
[ADDRESS_653037] operating procedures.  Deviations will be reviewed and signed off by [CONTACT_456]. If 
deviations are observed/reported that significantly affect or have the potential to significantly 
affect human subject protection or reliability of the trial re sults, then LABORIE will conduct a 
root cause analysis and implement appropriate corrective and preventative actions.  
16 AMENDMENTS  
If there are any changes to the protocol during the application of the study or during the length 
of the clinical study in prog ress, the IRB will be notified for review.  During an ongoing study if 
an amendment is made to the protocol the amended protocol will be sent to the applicable 
institution within the timelines required.  The Investigator should not implement any deviation 
from, or changes to the clinical protocol without agreement by [CONTACT_206722]/favourable opi[INVESTIGATOR_206684], except when 
necessary to eliminate an immediate hazard(s) to a clinical study subject. In s ome instances, an 
amendment may require a change to the Informed Consent Form. The investigator must 
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 32 of 35 
 
receive an IRB approval/favourable opi[INVESTIGATOR_206685].  
[ADDRESS_653038] Stipends or Payments  
Subjects will be offered a $[ADDRESS_653039] 
of parking and/or meals required during their clinic visit.   
The Sponsor has covered this study by [CONTACT_206723]. The certificate of insurance evidencing the coverage, 
insurance company, policy number and the sum insured are provided in the Study’s File.  
17.3 Committees  
A Data Monitor Committee will no t be utilized in this study based on the evaluation of the level 
of potentia l risks.  
17.4 Study Timetable  
PROPOSED STUDY TIMELINE  TOTAL DURATION (WEEKS)  ACTUAL DATES  
PROPOSED SITE TRAINING & INITIATION 
PHASE  1  July 2018  
PROPOSED RECRUITMENT (1st subject  in 
to last subject  out) 8 July- September 2018  
PROPOSED DATABASE LOCKOUT  1 October 2018  
PROPOSED STUDY REPORT 
COMPLETION  3 October 2018  
TOTAL (WEEKS / MONTHS)  -  
ESTIMATED COMPLETION (QUARTER)  Start Q4 FY2018  End of October  [ADDRESS_653040] been obtained.  Any 
additional requirements imposed by [CONTACT_206724].  This study  will be conducted in 
compliance with all international laws and  regulations, and nation al laws and regulations of the 
countries in which the usability study  is performed, as well as any applicable guidelines.   
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 33 of 35 
 
19 PUBLICATION POLICY  
The results of the study may be submitted for publication, whether peer -reviewed or marketing 
materials. Publicat ion rights and details are covered in the Investigator Agreement, there may 
be other authors involved in the creation of the publication.  
20 ATTACHMENTS  
20.1 Informed Consent Documents  
- TDOC -NXT-01-ICF - Informed Consent Form  
 
20.2 Investigator’s Brochure  
- TDOC -NXT-01-IB T-DOC NXT Investigator’s Brochure  
 
20.3 Case Report Forms  
- TDOC -NXT-01- CRF1Case Report Form 1  
- TDOC -NXT-01- CRF2Case Report Form 2  
- TDOC -NXT-01- CRF3Case Report Form 3  
- TDOC -NXT-01- CRF4Case Report Form 4  
- TDOC -NXT-01- CRF5Case Report Form 5  
21 REFERENCES  
Abrams, P., Andersson K.E., Artibani W., Birder L., Bliss D., Brubaker L., Cardozo, L., Chapple, C., 
Cottenden, A., de Ridder D., Dmochowski R., Dumoulin C., Drake M., Fry C., Hanno P., 
Herschorn S., Kelleher C., Koelbl H., Khoury S., Madoff R., Maher C., Milsom I., Moore K.H., 
Moore K.N., Newman D., Nijman R., Rosier P., Staskin D., Thuroff J., Tubaro A., Vodusek D., 
Wein A. (2013) Recommendations of the International Scientific Committee: Evaluation 
and treatment of urinary incontinence, pelvic organ prol apse and faecal incontinence 
Abrams P., Cardozo L., Khoury S., Wein A. (Eds.) Incontinence: 5th International 
Consultation on Incontinence, Paris, February 2012 . (pp. 1904 -1907 ). ICUD -EAU.  
Chapple, C. R., MacDiarmid, S. A., & Patel, A. (2009). Urodynamics Made Easy . Elsevier Health 
Sciences.  
Cooper, M. A., Fletter, P. C., Zaszczurynski, P. J., & Damaser, M. S. (2011). Comparison of air -
charged and water -filled urodynamic pressure measurement  catheters. Neurourology and 
Urodynamics , 30(3), 329 –334. https://doi.org/10.1002/nau.[ZIP_CODE]  
Couri, B. M., Bitzos, S., Bhardwaj, D., Lockhart, E., Yue, A., & Gopi[INVESTIGATOR_007], I. (2017). Performance 
analysis of the T -DOC® air -charged catheters: An alternate technology for urodynamics. 
Neurourology and Urodynamics . https://doi.org/10.1002/nau.[ZIP_CODE]  
Digesu, G . A., Derpapas, A., Robshaw, P., Vijaya, G., Hendricken, C., & Khullar, V. (2014). Are the 
measurements of water -filled and air -charged catheters the same in urodynamics? 
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 34 of 35 
 
International Urogynecology Journal , 25(1), 123 –130. https://doi.org/10.1007/s00192 -
013-2182 -z 
Drzewiecki B.A., Bauer S.B. (2015) Urodynamics in the pediatric patient in I. Franco, P. Austin, 
S.B. Bauer (Eds.) Pediatric Incontinence: Evaluation and Clinical Management (pp 91 -98). 
West Sussex, [LOCATION_006]: Wiley -Blackwell. Retrieved July 21, 2017, f rom 
http://www.wiley.com/WileyCDA/WileyTitle/productCd -[PHONE_4442].html  
Fleiss , J.L., Levin , B., & Cho Paik , M. (2003). Statistical Methods for Rates and Proportions (3rd 
ed.). [LOCATION_001], NY: Wiley.  
Gammie, A., Clarkson, B., Constantinou, C., Damaser, M., Drinnan, M., Geleijnse, G., … (The 
International Continence Society Urodynamic Equipment Working Group). (2014). 
International continence society guidelines on urodynamic equi pment performance. 
Neurourology and Urodynamics , 33(4), 370 –379. https://doi.org/10.1002/nau.[ZIP_CODE]  
Gammie, A., Abrams, P., Bevan, W., Ellis -Jones, J., Gray, J., Hassine, A., … Hashim, H. (2016). 
Simultaneous in vivo comparison of water -filled and air -filled pressure measurement 
catheters: Implications for good urodynamic practice. Neurourology and Urodyna mics , 
35(8), 926 –933. https://doi.org/10.1002/nau.[ZIP_CODE]  
McKinney, T. B., Babin, E. A., Ciolfi, V., McKinney, C. R., & Shah, N. (2018). Comparison of water   
         and air  charged transducer catheter pressures in the evaluation of cystometrogram and    
         voiding pressure studies. Neurourology and Urodynamics , 37(4), 1434 –1440. 
         https://doi.org/10.1002/nau.[ZIP_CODE]  
Perez, L. M., & Webster, G. D. (1992). The history of urodynamics. Neurourology and  
        Urodynamics , 11(1), 1 –21. https://doi.org/10.1002/nau.[PHONE_4443]  
Rosier P.F.W.M., Schaefer W., Lose G., Goldman H.B., Guralnick M., Eustice S., et al. 
International Continence Society Good Urodynamic Practices and Terms 2016: 
Urodynamics, uroflowmetry, cystometry, and pressure -flow study. Neurourol Urodynam. 
2016 Dec 1;n/a -n/a. 
Rosier P .F. The evidence for u rodynamic investigation of patients with symptoms of urinary  
incontinence. F1000prime Rep.  2013;5:8. https://doi.org/10.[ZIP_CODE]/ P5 -8 
U.S. Department of Health and Human Services Food and Drug Administration Center for 
Devices and Radiological Health , Office of Device Evaluation Center for Biologics Evaluation 
Research (2014) Premarket Assessment of Pediatric Medical Devices – Guidance for 
Industry and Food and Drug Administration Staff.  Retrieved July 21, 2017 from: 
https://www.fda.gov/RegulatoryInformation/Guidances/ucm089740.htm   
U.S. Department of Health and Human Services Food and Drug Administration Center for 
Devices and Radiological Health, Office of Device Evaluat ion Center for Biologics Evaluation 
Research (2016) Applying Human Factors and Usability Engineering to Medical Device – 
Guidance for Industry and Food and Drug Administration Staff.  Retrieved Aug 8, 2017 
from: https://www.fda.gov/RegulatoryInformation/Guidances/ucm089740.htm   
Winters, J. C., Dmochowski, R. R., Goldman, H. B., Herndon, C. D. A., Kobashi, K. C., Kraus, S. R., 
… Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction. (2012). 
 T-DOC ® NXT Clinical Study 
Protocol  TDOC -NXT-01-PR Version 1.0  
 
Confidential © 2018 LABORIE   Uncontrolled when printed  Page 35 of 35 
 
Urodynamic studies in adults: AUA/SUFU guideline. The Journal of Urology, 188([ADDRESS_653041]), 
2464 –2472. https://doi.org/10.1016/j.juro.2012.09.081  
Unpublished References:   
. Urodynamic Clinical Testing.  Reference Doc#PD -TR-151-01 
 
